For Canadian cannabis companies, the industry offers plenty of international opportunities, and for as such the International Cannabis (TSXV:ICC) the story is no different; as such, the company announced on Monday (July 17), that it has been approved for the sale of recreational cannabis in Uruguay.
The actual product will be sold through the country’s approved network of sales, with only two non-medical products for adult-use available, sealed in 5-gram packaging with a $6.50 cost per unit.
In the company’s press release, ICC shared a report from the Institute of Regulation and Control of Cannabis (IRCCA), stating the company would be able to begin the sale of “psychoactive cannabis for non-medical use in pharmacies” by July 19.

Restrictions for the recreational cannabis market in Uruguay

Uruguay has taken significant steps forward when it comes to the legalization of cannabis and has served as a test base model for other markets to use as part of their own legalization path.
In April of this year, it became legal in Uruguay for consumers to buy cannabis in pharmacies. However, there is a vigorous regulation system for consumers to go through in order to legally obtain the product. According to CNBC, there is a national registry for only local residents to apply, and a monthly maximum of 40 gram per person.
“[V]endors can only sell the drug in 5-gram containers, although 10-gram containers are expected to be introduced later,” CNBC reported
Alejandro Antalich, CEO of ICC said the company would continue the construction of a CBD extraction laboratory in Uruguay, the project currently has an intended April 2018 date for its launch.


Investor Takeaway

ICC has a 70,000 square foot greenhouse, entirely dedicated to the production of adult-use cannabis and it plans to increase the production of CBD dried flower to approximately 160 tons per year.
Recent market research from analyst Neal Gilmer at Mackie Research Capital indicated the company had a worthwhile return thanks to the potential of its expansion in the South American market. Gilmer stamped ICC with a “Tentative Buy” for his report in December of 2016.
At the close of trading on Monday, the company’s share price had increased 2.7 percent over a one-day trading period to reach $1.14. Year-to-date, shares of ICC are up 17.53 percent.
Don’t forget to follow us @INN_LifeScience and @INN_Cannabis for real-time news updates.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Trading resumes in:

Company: 4Front Ventures Corp.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info: www.bgandg.com/tcmd

Keep reading... Show less

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less